patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID-19 severe or critically
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.80 [0.63, 1.01]< 1 45% 33 studies (32/1) 97.0 % moderate critical moderate crucial - death or transfer to ICU 0.90 [0.73, 1.10]< 1 18% 2 studies (1/1) 84.5 % NA not evaluable crucial - deaths 0.68 [0.53, 0.87]< 1 92% 74 studies (54/20) 99.9 % moderate critical moderate crucial - deaths (time to event analysis only) 0.83 [0.50, 1.38]< 1 96% 17 studies (13/4) 76.4 % moderate critical moderate crucial - clinical deterioration 0.61 [0.44, 0.86]< 1 0% 5 studies (5/-) 99.8 % some concern serious moderate important - clinical improvement 1.34 [1.14, 1.58]> 1 58% 22 studies (22/-) 100.0 % some concern critical moderate important - clinical improvement (14-day) 1.43 [1.08, 1.91]> 1 51% 8 studies (8/-) 99.3 % some concern serious moderate important - clinical improvement (21-day) 1.50 [0.22, 10.08]> 1 0% 1 study (1/-) 66.1 % NA not evaluable important - clinical improvement (28-day) 1.48 [1.06, 2.05]> 1 44% 10 studies (9/1) 99.0 % moderate critical moderate important - clinical improvement (7-day) 2.39 [0.73, 7.80]> 1 45% 3 studies (3/-) 92.5 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.15 [1.00, 1.33]> 1 34% 11 studies (11/-) 97.7 % some concern critical moderate important - death or ventilation 1.07 [0.74, 1.56]< 1 47% 6 studies (6/-) 35.6 % some concern not evaluable moderate important - hospital discharge 1.24 [0.92, 1.67]> 1 48% 7 studies (6/1) 92.1 % low serious high important - mechanical ventilation 0.87 [0.67, 1.12]< 1 0% 16 studies (16/-) 86.4 % some concern low moderate important - mechanical ventilation (time to event analysis only) 0.66 [0.25, 1.72]< 1 0% 1 study (1/-) 80.2 % NA not evaluable important - radiologic improvement (14-day) 4.02 [1.61, 10.05]> 1 0% 3 studies (3/-) 99.9 % some concern not evaluable moderate important - viral clearance 6.97 [0.23, 210.35]> 1 89% 2 studies (2/-) 86.4 % some concern not evaluable moderate important - viral clearance by day 14 7.68 [0.34, 173.70]> 1 90% 2 studies (2/-) 89.7 % some concern not evaluable moderate important - ICU admission 0.53 [0.35, 0.83]< 1 46% 9 studies (8/1) 99.8 % moderate not evaluable moderate non important - off oxygenation 1.65 [0.05, 50.02]> 1 81% 2 studies (2/-) 61.1 % high not evaluable low non important - recovery 1.30 [0.64, 2.66]> 1 9% 2 studies (2/-) 76.5 % low not evaluable high non important - 00 related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - serious adverse events 1.07 [0.87, 1.32]< 1 26% 17 studies (17/-) 24.7 % some concern low moderate important - superinfection 1.32 [0.48, 3.60]< 1 80% 4 studies (3/1) 29.6 % serious not evaluable low important - acute kidney injury 0.43 [0.14, 1.34]< 1 0% 1 study (-/1) 92.7 % NA not evaluable non important - adverse events 1.13 [0.96, 1.32]< 1 0% 12 studies (12/-) 7.0 % some concern low moderate non important - arrhythmia 0.16 [0.03, 0.90]< 1 0% 1 study (-/1) 98.1 % NA not evaluable non important - elevated liver enzymes 0.52 [0.18, 1.51]< 1 0% 1 study (-/1) 88.5 % NA not evaluable non important - Myocardial infarction 0.87 [0.19, 3.92]< 1 0% 1 study (-/1) 57.2 % NA not evaluable non important - venous thromboembolism 5.23 [0.42, 65.62]< 1 0% 1 study (-/1) 10.2 % NA not evaluable non important -
LoD: level of statistical demonstration:
